Innovative Health Claims Approved by Authorities Confirms Benefits of L. rhamnosus HA-114 to Support Weight Management Efforts

Lallemand Health Solutions has gained innovative indications for its probiotic strain L. rhamnosus HA-114 from Health Canada, recognizing its beneficial impact to support people’s efforts when engaged in a weight management program, at a daily dose of 10B CFU.

This recognition from Canadian authorities follows the results of a breakthrough study on the impact of a probiotic supplementation on the response of overweight, otherwise healthy, individuals engaged in a weight-reducing program, highlighting the beneficial effects of the probiotic intervention on eating behaviors, mental health, and metabolic profile.  L. rhamnosus HA-114 was granted the following health claims, which are the first indications of their kind in the very competitive weight management category:

• Helps support restraint to eat in individuals involved in a weight management program.
• Could be a complement to a healthy lifestyle that incorporates a calorie-reduced diet and regular physical activity for individuals involved in a weight management program.

“Bringing innovative, science-based, regulatory-approved solutions to enhance one’s lifestyle is a key element of our global mission at Lallemand Health Solutions” affirms Solange Henoud, Vice-president, Regulatory and Compliance.  “We are proud that our probiotic strain is now officially recognized by our regulators to help sustain the efforts engaged by individuals during their weight management program” she adds.

About L. rhamnosus HA-114

In a recent, randomized, double-blind, placebo-controlled clinical trial, 152 overweight, otherwise healthy, adults starting a diet were recruited [Choi, 2021 – Approved for publication]. While on a personalized energy-restricted diet (-500 kcal per day), participants were randomized to either take L. rhamnosus HA-114 or placebo. Physiological and psychological parameters and eating behaviors using validated questionnaires were measured at baseline and at 12 weeks. In the probiotic group, eating behaviors such as binge eating, lack of control over eating or cravings significantly reduced over the course of the study.  Also, L. rhamnosus HA-114 significantly influenced plasma insulin, homeostatic model assessment of insulin resistance (HOMA-IR), low-density lipoprotein (LDL) cholesterol and triglycerides over the study period when compared with baseline, demonstrating the strain’s beneficial effects on the maintenance of a healthy metabolic profile in overweight participants while on a calorie-restricted diet. The results show the beneficial effects of the probiotic intervention on eating behaviors, mental health, and metabolic profile and reinforce the validity of the brain-gut axis concept.

L. rhamnosus HA-114 is a unique patent pending probiotic strain from Lallemand Health Solutions. For more information, download the detailed study here.

About Lallemand Health Solutions

Lallemand Health Solutions is a vertically integrated probiotic manufacturer specialized in the research, development, production and marketing of probiotic yeast and bacteria. It’s ready-to-market and custom probiotic formulations target specific populations and health segments, including gut health, immune health, mental health, women’s health, skin health, oral health, metabolic health, and sport. From lab to shelf, Lallemand Health Solutions has the full control and expertise to produce premium probiotic solutions, blends and custom formulations in cutting-edge plants certified to the highest quality. More than 600 probiotic formulas are currently marketed in over 60 countries across five continents.

 

MEDIA CONTACT

Marilou Luneau
Content Manager, Lallemand Health Solutions
mluneau@lallemand.com